



HHS Public Access

Author manuscript

Nat Genet. Author manuscript; available in PMC 2017 August 23.

Published in final edited form as:

Nat Genet. 2017 January ; 49(1): 125–130. doi:10.1038/ng.3738.

Multiethnic genome-wide meta-analysis of ectopic fat depots identifies loci associated with adipocyte development and differentiation

A full list of authors and affiliations appears at the end of the article.

INTRODUCTORY PARAGRAPH

Variation in body fat distribution contributes to the metabolic sequelae of obesity. The genetic determinants of body fat distribution are poorly understood. The goal of this study was to gain new insights into the underlying genetics of body fat distribution by conducting sample-size weighted

ADDRESSES FOR CORRESPONDENCE: Audrey Y Chu, PHD, NHLBI's Framingham Heart Study, Framingham MA 01702 USA, audrey.chu@nih.gov, Matthew L. Steinhauser, MD, Brigham and Women's Hospital and Harvard Medical School, Boston MA 02115 USA, msteinhauser@partners.org, Caroline S Fox, MD MPH, NHLBI's Framingham Heart Study, Framingham MA 01702 USA, foxca@nhlbi.nih.gov.

⁴⁸These authors contributed equally to this work

⁴⁹This author is deceased

⁵⁰These authors jointly supervised this work

Data availability statement: Summary statistics for all meta-analyses will be made available at the following website <https://www.nhlbi.nih.gov/research/intramural/researchers/ckdgen>.

Author contributions

Study design: X Guo, AH Kissebah, J Kullberg, LJ Launer, M Olivier, PA Peyser, IB Borecki, DW Boden, SA Czerwinski, J Ding, V Gudnason, TB Harris, C Langefeld, L Lind, Y Liu, JI Rotter, B Towne, M Allison

Study management: Yi Zhang, LJ Launer, M Olivier, PA Peyser, JG Terry, IB Borecki, DW Boden, JJ Carr, SA Czerwinski, V Gudnason, TB Harris, L Lind, BD Mitchell, TH Mosely, Jr, JI Rotter, AR Shuldiner, H Völzke, JG Wilson, M Allison

Subject recruitment: AH Kissebah, J Kullberg, MK Wojczynski, DW Boden, SA Czerwinski, V Gudnason, L Lind, BD Mitchell, TH Mosely, Jr, AR Shuldiner, B Towne, H Völzke

Interpretation of results: AY Chu, X Deng, VA Fisher, Yang Zhang, MF Feitosa, C Liu, O Weeks, AC Choh, Q Duan, X Guo, NL Heard-Costa, X Liu, L Lu, JR O'Connell, A Parihar, AV Smith, Yi Zhang, AH Kissebah, M Olivier, PA Peyser, JG Terry, MK Wojczynski, LF Bielak, IB Borecki, DW Boden, JJ Carr, SA Czerwinski, J Ding, N Friedrich, SL Kardia, C Langefeld, Y Liu, BD Mitchell, JI Rotter, AR Shuldiner, B Towne, H Wallaschofski, M Allison, CM Lindgren, W Goessling, LA Cupples, ML Steinhauser, CS Fox

Drafting manuscript: AY Chu, Yang Zhang, MF Feitosa, X Guo, JW Kent Jr., Yi Zhang, AH Kissebah, MK Wojczynski, IB Borecki, CM Lindgren, ML Steinhauser, CS Fox
Critical review: AY Chu, X Deng, VA Fisher, MF Feitosa, C Liu, O Weeks, AC Choh, X Guo, NL Heard-Costa, JW Kent Jr., X Liu, L Lu, A Mahajan, JR O'Connell, A Parihar, Yi Zhang, G Homuth, AH Kissebah (deceased), J Kullberg, M Nauck, M Olivier, PA Peyser, JG Terry, LF Bielak, J Blangero, IB Borecki, DW Boden, JJ Carr, SA Czerwinski, J Ding, N Friedrich, E Ingelsson, SL Kardia, C Langefeld, L Lind, Y Liu, BD Mitchell, AP Morris, TH Mosely, Jr, JI Rotter, AR Shuldiner, B Towne, H Völzke, H Wallaschofski, M Allison, CM Lindgren, W Goessling, LA Cupples, ML Steinhauser, CS Fox

Statistical methods and analysis: AY Chu, X Deng, VA Fisher, A Drong, Yang Zhang, MF Feitosa, AC Choh, Q Duan, TD Dyer, JD Eicher, X Guo, NL Heard-Costa, T Kacprowski, JW Kent Jr., LA Lange, X Liu, K Lohman, L Lu, A Mahajan, JR O'Connell, A Parihar, JM Peralta, AV Smith, J Yao, LF Bielak, J Ding, C Langefeld, Y Liu, BD Mitchell, AP Morris, CM Lindgren

Genotyping: Yi Zhang, G Homuth, M Olivier, DW Boden, SA Czerwinski, E Ingelsson, SL Kardia, Y Liu, AP Morris, JI Rotter, AR Shuldiner, B Towne, CM Lindgren

Bioinformatics: AY Chu, X Deng, VA Fisher, MF Feitosa, C Liu, AC Choh, JD Eicher, AD Johnson, T Kacprowski, AV Smith, Yi Zhang

Data collection: Yang Zhang, O Weeks, R Laqua, N Friedrich, W Goessling, ML Steinhauser

Animal work/functional data: Yang Zhang, ML Steinhauser

Disclosures: Caroline S. Fox and Audrey Y. Chu are employed by Merck Research Laboratories as of December 14, 2015 and July 18, 2016, respectively.

Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. Please see Supplementary Note for acknowledgements and funding sources.

fixed-effects genome-wide association meta-analyses in up to 9,594 women and 8,738 men for six ectopic fat traits in European, African, Hispanic, and Chinese ancestry populations, with and without sex stratification. In total, 7 new loci were identified in association with ectopic fat traits (*ATXN1*, *UBE2E2*, *EBF1*, *RREB1*, *GSDMB*, *GRAMD3* and *ENSA*; $P < 5 \times 10^{-8}$; $FDR < 1\%$). Functional analysis of these genes revealed that loss of function of both *ATXN1* and *UBE2E2* in primary mouse adipose progenitor cells impaired adipocyte differentiation, suggesting a physiological role for *ATXN1* and *UBE2E2* in adipogenesis. Future studies are necessary to further explore the mechanisms by which these genes impact adipocyte biology and how their perturbations contribute to systemic metabolic disease.

Keywords

GWAS; obesity; ectopic fat; adipocyte development; differentiation

MAIN TEXT

Variation in body fat distribution is associated with cardiometabolic risk, including diabetes, hypertension and coronary heart disease,^{1–5} and is at least partially independent of total adiposity. Adipose tissue can be quantified non-invasively using computed tomography (CT) and magnetic-resonance imaging (MRI) to measure fat volume and fat attenuation in different tissue compartments. We previously demonstrated that both indices, in addition to relative fat distribution, are important predictors of cardiometabolic risk.^{6–11}

Several lines of evidence suggest a unique genetic component to body fat distribution. First, indices of body fat distribution are heritable with values ranging from 36–47%, even after adjustment for body mass index (BMI).¹² Second, unique genetic loci exist for body fat distribution. For example, we identified a SNP associated with pericardial fat¹³ that was not associated with visceral fat,¹² BMI or waist-hip-ratio (WHR).^{14,15} Third, several lipodystrophy syndromes, characterized by abnormal body fat distribution, are genetically mediated.¹⁶

The current study presents a genome-wide association study and meta-analysis of adipose tissue traits derived from imaging biomarkers (Supplementary Table 1) from 2.6 million SNPs in up to 9,594 women and 8,738 men of European, African, Hispanic and Chinese ancestry (see Supplementary Tables 2, 3 and 4) and uses mouse models to characterize selected loci.

Subcutaneous and visceral adipose tissue (SAT, VAT) were previously estimated to have heritabilities of 57% and 36%, respectively^{12,17} (Supplementary Table 5). To assess the genetic contribution to variation in fat attenuation traits, which serve as indirect markers of fat quality (SAT Hounsfield Units [SATHU] and VATHU), heritability (H^2) was estimated in 3,312 women and men in the Framingham Heart Study (FHS), and found to be between 29–31% ($P < 1 \times 10^{-15}$). To assess the shared genetic contribution between ectopic fat traits, the genetic correlations were estimated among 3,336 women and men in FHS. Moderate to strong statistically significant correlations were observed between almost all ectopic fat traits pairs (0.35 to 0.67 and -0.74 to -0.35 , all $P < 5 \times 10^{-4}$; Supplementary Table 6), suggesting

shared loci between ectopic fat traits. However, not all genes were shared between traits ($P < 5 \times 10^{-11}$ for non-overlapping correlations for all pairwise comparisons). The genetic correlations across the ectopic fat traits are also reflected in the phenotypic correlations (Supplementary Table 7).

In this combined multiethnic sample-size weighted fixed-effects meta-analysis^{18,19} of up to 18,332 participants, a total of 11 locus-trait associations (7 novel and 4 known) attained genome-wide significance ($P < 5 \times 10^{-8}$) out of 27 genomic scans (from analysis of 9 traits and models in 3 strata – overall, women and men). Of the 7 novel loci, 3 were associated with volumetric subcutaneous (*GSDMB*) and visceral fat traits (*GRAMD3* and *RREB1*), 2 were associated with pericardial fat (*ENSA* and *EBF1*), 1 was associated with fat attenuation (*ATXN1*), and 1 was associated with relative fat distribution (VAT/SAT ratio [*UBE2E2*]) (Table 1; Supplementary Figures 1a–g; with imputation quality in Supplementary Table 8). Associations were robust across ancestry-stratified sensitivity analyses (Supplementary Figures 2a–g and 3a–g; Supplementary Table 9). Manhattan plots and QQ plots for each analysis showed minimal inflation of association test statistics (Supplementary Figures 4a–g). The remaining 4 loci (*LYPLAL1*, *LY86*, *FTO*, *TRIB2*) attaining genome-wide significance were previously identified.^{12,13}

rs2123685, located between the 3' untranslated regions of *ZBPB2* and *GSDMB*, was associated with SAT in women only ($P_{\text{women}} = 3.4 \times 10^{-8}$, Supplementary Table 10a). Investigation of related ectopic traits among women revealed a direction-consistent nominal association with VAT ($P = 4.8 \times 10^{-4}$). SNPs at *FTO*, the canonical-BMI locus, attained genome-wide significance in association with SAT in the overall sample ($P = 1.4 \times 10^{-9}$).

The newly identified association at *RREB1* with VATadjBMI (rs2842895, $P = 1.1 \times 10^{-8}$) was observed in the overall sample and both sexes (Supplementary Table 10b). Examination of related ectopic traits demonstrated nominal associations with VAT and VAT/SAT ratio adjBMI ($P = 4.8 \times 10^{-5}$ and $P = 8.9 \times 10^{-6}$ respectively). The newly identified association of rs10060123 near *GRAMD3* for VATadjBMI was specific to women ($P = 4.5 \times 10^{-8}$). This locus was nominally associated with VAT and VAT/SAT ratio adjBMI in women (Supplementary Table 10c).

PAT represents distinct ectopic fat deposition around the heart. Two findings in the overall sample at the *ENSA* and *EBF1* loci ($P = 2.8 \times 10^{-9}$ and 1.0×10^{-9} , respectively, Table 1) have not been previously associated with ectopic fat, general adiposity or body fat distribution. Associations at *ENSA* and *EBF1* did not appear to be sex-specific (Supplementary Tables 10d and 10e). Further investigation of the *ENSA* and *EBF1* loci showed no associations with SAT, VAT or VAT/SAT ratio, underscoring their specificity to PAT. *TRIB2* was associated with PAT in this and our prior meta-analysis ($P < 5 \times 10^{-8}$).¹³

Cellular characteristics of fat quality, such as lipid content, vascularity, and adipocyte size and number, may be important factors influencing metabolic risk,^{7,10} but direct assessment is invasive. Fat attenuation traits, assessed with computed tomography, are correlated with fat quality characteristics^{20,21} and thus represent indirect markers of fat quality. *ATXN1* was associated with SATHU among men only ($P = 1.4 \times 10^{-8}$) with no association among women

($P=0.36$, Supplementary Table 10f). Examination of related ectopic fat traits indicated similar direction of association with VAT/HU, and opposite direction for SAT and VAT (Supplementary Table 10f) which is consistent with epidemiology findings.⁷

The ratio of visceral to subcutaneous fat volumes (VAT/SAT ratio) represents the propensity to store fat viscerally. *UBE2E2* was associated with VAT/SAT ratio ($P=3.1\times 10^{-10}$); a nominal association was also identified with VAT ($P=1.4\times 10^{-3}$) but not SAT, suggesting the finding is mostly driven by the higher relative abundance of VAT. The direction of association in both sex strata was consistent (Supplementary Table 10g). Two known body fat distribution loci, *LYPLAL1* and *LY86*, were also associated with VAT/SAT ratio at genome-wide significance (Table 1), consistent with our prior analyses.^{12,22}

Calculation of false discovery rate (FDR) to account for multiple testing across the 27 meta-analyses showed all ectopic fat loci that attained genome-wide significance in each individual GWAS ($P<5\times 10^{-8}$) also attained an $FDR<1\%$.

To examine the association of the 7 newly identified ectopic fat loci with BMI and WHR, cross-trait evaluations for each lead SNP were performed in the most recent GIANT meta-GWAS, with sample sizes ~10–20 times larger than the current study.^{14,15} Only 2 out of 14 SNP-trait (BMI or WHR) associations were significant after Bonferroni correction for multiple testing ($P<0.05/14=3.6\times 10^{-3}$; Supplementary Table 10a-g), highlighting the specificity and uniqueness of the ectopic fat loci.

To evaluate the relationship between the known 97 BMI and 49 WHR loci^{14,15} and ectopic fat traits, we examined the association for these loci with fat volume and relative fat volume traits among the combined multiethnic sample of women and men. Because the ectopic fat data may be underpowered to determine statistically significant results, we hypothesized that the direction of the BMI and WHR findings would be directionally consistent with abdominal ectopic traits, even if the p-values were not significant (Supplementary Table 11). Direction consistent SNP-trait associations between SAT and BMI were observed for 87 of 97 loci ($P_{\text{binomial}}=8.9\times 10^{-17}$). When restricted to the 27 loci nominally associated with SAT ($P_{\text{SAT}}<0.05$), all 27 SNP-SAT associations were directionally consistent with BMI ($P_{\text{binomial}}=7.5\times 10^{-9}$). SAT is not an ectopic fat depot and may represent a metabolic sink for healthier fat storage that is highly correlated with BMI and shares genetic risk factors (as shown with the enriched number of direction consistent associations), yet also represents a unique metric of fat distribution with unique genetic influences (as shown with the *GSDMB*-SAT association). No other traits showed directionally consistent associations with the BMI or WHR (all $P>0.05$). These results further underscore how ectopic fat traits are uniquely disparate traits as compared to BMI and WHR.

Ectopic fat depots are associated with cardiometabolic risk and cardiovascular events.^{8–11} To gain insight into potential mechanisms linking these conditions, we evaluated the association of the new ectopic fat loci with traits from large-scale genetics consortia. Of 66 pairs of lead SNP-trait associations examined, 3 associations (*UBE2E2*-type 2 diabetes [T2D], *EBF1*-triglycerides, and *EBF1*-HDL cholesterol) were statistically significant after Bonferroni correction for multiple testing ($P<0.05/66=8\times 10^{-4}$; Supplementary Table 12).

To examine if any of the new variants overlap with known regulatory regions in adipose tissue, lead SNPs and variants in linkage disequilibrium (LD) with the lead SNPs ($r^2 > 0.8$) were interrogated using ENCODE Consortium data implemented in HaploReg²³ and RegulomeDB.²⁴ Except for *ATXN1*, all other loci contained SNPs in LD with the lead SNP that overlapped with known regulatory regions in adipose tissue. For example, the lead *UBE2E2* variant (rs7374732), and other SNPs in LD, overlapped with a known enhancer region in adipose derived stem cells (Supplementary Table 13).

The list of candidate loci was further prioritized based on visual examination of regional association plots (Supplementary Figures 1a–g) and identification of 1) a localized association within a gene body at each locus (*RREB1*, *ATXN1* and *UBE2E2*), or 2) a localized association near the gene body concomitant with the lack of other genes within 1Mbp of the lead SNP (*EBF1*). In applying these criteria, four genes were selected for additional functional study.

To test the hypothesis that inter-depot differences in gene expression or their dynamic regulation during adipocyte development would identify candidates with a higher likelihood of functional significance, expression of 4 genes (*Ebf1*, *Rreb1*, *Atxn1*, *Ube2e2*) in murine SAT, VAT, and PAT depots was assessed by qPCR. *Ube2e2* was expressed more highly in the perigonadal VAT of 6 week-old C57BL/6 mice relative to the SAT (2.1 fold, $p < 0.05$, $n = 5$) or PAT (2.6 fold, $p < 0.01$, $n = 5$), but no differences were observed for *Ebf1*, *Rreb1* or *Atxn1* (Figure 1a). Differential gene expression of these 4 genes was also assessed in murine diet-induced obesity. A 2.1 fold induction of *Atxn1* expression in SAT of diet-induced obese mice was observed relative to lean controls ($p < 0.05$, $n = 6$). Significant differences were not observed for *Ebf1*, *Rreb1*, or *Ube2e2* in response to the obesogenic stimulus (Figure 1b).

To explore a potential role for the candidate genes in adipocyte development, we examined their regulation during *ex vivo* adipogenic differentiation of progenitor-rich stromal-vascular cell fractions isolated from the subcutaneous and visceral depots of C57BL/6 mice. Candidate gene expression was measured at regular intervals during adipogenic differentiation. In progenitors isolated from both VAT and SAT, we observed a significant down-regulation of *Atxn1*, *Ube2e2*, and *Ebf1* during adipogenesis (Figure 1c and Supplementary Figure 5). However, in all three instances the expression returned to near baseline levels by 96h post-adipogenic induction. In contrast, no significant transcriptional regulation of *Rreb1* after adipogenic induction was observed (Supplementary Figure 5).

Both *Atxn1* and *Ube2Ee2* showed evidence of dynamic regulation of gene expression during adipogenesis with variable depot-specific expression in the murine models providing rationale to further explore their functional significance with a genetic loss-of-function assay. Knock-down of both genes with specific shRNA retroviral constructs during *ex vivo* adipogenesis of SAT progenitors impaired the formation of lipid-containing adipocytes relative to vector control infected cells, whereas only *Ube2e2* knock-down impaired adipogenesis in progenitors isolated from VAT (Figure 1d,e).

Our findings provide insight into the genetics of body fat distribution. The scant number of significant associations observed between the ectopic fat loci and more general measures of

adiposity, such as BMI and WHR,^{14,15} demonstrates the specificity of the ectopic fat associations, highlights the utility of precise phenotyping of fat distribution, and suggests different mechanisms involved in ectopic fat storage compared to more general adiposity measures. This specificity was particularly notable for PAT loci, which demonstrate no associations with SAT, VAT, VAT/SAT ratio, BMI or WHR.

In addition, few cross-trait associations were observed for ectopic fat loci and other cardiometabolic traits, which is striking given the epidemiologic associations between ectopic fat and cardiometabolic risk¹⁻⁵. One notable exception is *UBE2E2*, which is a known T2D locus^{25,26}. The lead T2D SNP does not appear to be in LD with the lead SNP from our study ($r^2[\text{rs7374732}, \text{rs7612463}] < 0.08$ across all HapMap2 populations), and therefore likely represents an independent signal. The major allele at rs7374732 is associated with both lower VAT/SAT ratio and lower risk of T2D, suggesting that targeting relative fat distribution may have beneficial downstream effects.

Functional studies support a physiologic role for *UBE2E2* and *ATXN1* through regulation of adipocyte differentiation. *ATXN1* encodes a chromatin binding factor involved in the repression of Notch signaling. It has been implicated in neurologic diseases, including spinocerebellar ataxia 1, but there are no reported associations between SNPs in *ATXN1* and adiposity-related traits. In contrast, *UBE2E2* is a known T2D GWAS locus,²⁵⁻²⁷ although the markers are in low LD with the lead SNP in the present study. *UBE2E2* (3p24.2) encodes the ubiquitin-conjugating enzyme E2E2, which is expressed in human pancreas, liver, muscle and adipose tissues. The present GWAS results highlight *UBE2E2* in association with the VAT/SAT ratio, a measure of the relative propensity to store fat in the visceral cavity rather than the subcutaneous compartment. We therefore speculate that SNP-associated modulation of gene expression or function of the protein products may impact adiposity through an effect on adipocyte differentiation and relative impairments in adipocyte development may partially explain a default propensity to deposit viscerally as compared to subcutaneously.

Given the uniqueness of the ectopic fat traits, the sample size was limited in comparison to other meta-analyses. Moreover, identification of candidate genes based on proximity to a GWAS signal may miss long distance interactions between genes and regulatory domains. In contrast, multiethnic analyses, such as this study, not only enhance generalizability, but may also boost power for certain traits, particularly in contexts of limited allelic heterogeneity. The possibility of false positive loci is also a consideration, given the absence of external replication. However, all newly identified loci passed $\text{FDR} < 1\%$. Such statistical limitations are further mitigated in the case of *ATXN1* and *UBE2E2* by functional validation of these loci in murine adipose tissue.

Combining large-scale discovery human genetics with the detailed fat phenotyping and experiments in model organisms identified 7 new loci in association with ectopic fat traits, of which *ATXN1* and *UBE2E2* demonstrated a functional effect during adipocyte differentiation. Future studies should further explore the exact mechanism by which modulation of *ATXN1* and *UBE2E2* impact adipocyte differentiation and whether this effect causally impacts systemic metabolic disease.

Online Methods

Study Participants

Up to 18,332 participants from 13 cohorts of European and African ancestry were available for analysis of subcutaneous and visceral adipose tissue volumetric traits, up to 11,596 from 6 cohorts of European, African, Asian, and Hispanic ancestry were available for analysis of pericardial adipose volumetric traits, up to 12,519 participants from 5 cohorts of European and African ancestry were available for analysis of attenuation traits, and up to 18,191 participants from 6 cohorts of European and African ancestry were available for analysis of relative fat distribution traits. This epidemiological sample constitutes the largest known collection of participants with radiologically derived ectopic fat measures and genetic data at the inception of this project. Supplementary Table 2 and 3 contain information regarding imaging modality used by each cohort, distribution by sex and ancestry per cohort for each trait analyzed and cohort descriptive information. All participants provided informed consent and each study was approved by their governing ethics committee.

Trait assessment

The traits measured in this study can be categorized into three groups: 1) fat volume measurements: subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) and pericardial adipose tissue (PAT); 2) fat attenuation measurements: subcutaneous adipose tissue attenuation (SATHU) and visceral adipose tissue attenuation (VATHU); and 3) relative fat distribution measurements: visceral-to-subcutaneous adipose tissue volume ratio (VAT/SAT ratio). All volume-based measures were assessed by computed tomography (CT) or magnetic resonance imaging (MRI) following study-specific protocols; attenuation-based measures were assessed by CT following study specific protocols. Please see Supplementary Table 2 and Supplementary Note for further detail.

The following traits were created by each cohort in the overall sample, women and men: volume-based traits - SAT, VAT, VAT adjusted for BMI, PAT, PAT adjusted for height and weight; attenuation-based traits - SATHU and VATHU; relative-distribution traits - VAT/SAT ratio, VAT/SAT ratio adjusted for BMI pericardial traits. The rationale for including the ectopic fat traits, the adjustment models, and the sex-stratified analyses was 4-fold. First, ectopic fat measures are correlated with each other and with general adiposity and we wished to adjust for these factors as potential confounders or intermediates and to examine the genetic associations independent of the adjustment factor. Please see refer to Supplementary Table 7 for pairwise correlations of all traits within FHS, the largest participating cohort. For example, the correlation between VAT and BMI is 0.71 to 0.75 and adjusting for BMI when examining VAT provides the relative amount of VAT controlling for degree of general adiposity. Although the correlations between VAT/SAT ratio and BMI are modest, adjusting for BMI allowed us to examine the propensity to store fat viscerally compared to subcutaneously independent of general adiposity. Second, adjustment of covariates reduces the residual variance of the trait associated with the given covariate and thus increases power to detect genetic associations. Third, in the adiposity genetics literature there is evidence of sexually dimorphic loci in which the variance explained is larger in women versus men²⁸ and association of the loci is markedly stronger in women compared to

men, and vice versa.^{14,22} Lastly, we adjusted PAT for height and weight to be consistent with our prior work¹³ (see Supplementary Table 1 for guide to nomenclature for traits and adjustment models).

Due to the known differences in body fat distribution by sex, each cohort created sex- and ancestry-specific residuals adjusted for age, age-squared, smoking status, measures of subpopulation stratification and family structure (if necessary). Family-based studies created an additional set of residuals from all participants (both women and men) to account for family structure when analyzing the overall sample. Participants with missing genotype, phenotype or covariate data were excluded from analysis as pre-specified in the analysis plan.

Study Specific Protocol

Trait measurements and descriptions from each cohort are available in Supplementary Material under “Cohort Specific Information and Protocols”.

Genotyping and Imputation

Each cohort was genotyped as specified in Supplementary Table 4 and performed ancestry-specific imputation up to ~2.6 million SNPs based on the HapMap Project Phase 2 haplotypes (<http://hapmap.ncbi.nlm.nih.gov/index.html.en>). All newly identified loci were imputed with imputation qualities >0.8 in each cohort. Imputation quality by locus and cohort are available in Supplementary Table 8.

Heritability Analysis

Heritability was estimated from the Framingham Heart Study using variance components analysis in SOLAR.¹⁶

Genetic Correlation Analysis

Pairwise genetic correlations between subcutaneous fat (volume and attenuation), visceral fat (volume and attenuation), ratio of visceral-to-subcutaneous fat and BMI were calculated using SOLAR¹⁶ in the Framingham Heart Study among 3,312 participants. We used residuals adjusted for age and sex. Two separate hypotheses were tested: 1) $RhoG = 0$ is the test for overlapping genetic correlations, and 2) absolute value ($RhoG$) = 1 is the test for non-overlapping genetic correlations.

Statistical Analysis

Within each cohort, by ancestry and by sex, genome-wide linear regression analyses were conducted on the 11 trait and model combinations assuming an additive genetic model using allele dosages. All traits approximated a normal distribution and untransformed traits were used for analysis. To prevent the undue influence of rare variants and/or of poorly imputed SNPs, we included variants with a minor allele count >10 and imputation quality >0.4 (for MaCH²⁹) or >0.3 (for IMPUTE³⁰) in each cohort.

For multiethnic analysis, we combined all cohort-specific results using a sample size-weighted fixed-effects meta-analysis (Stouffer’s method) as implemented in METAL^{18,19} to

allow for differences in trait measurement and scaling due to different imaging modalities across cohorts. European and African ancestry cohorts contributed to all ectopic fat traits; Chinese and Hispanic ancestry cohorts contributed only to pericardial volume traits (Supplementary Table 3). All analyses were performed for the overall sample (ALL), among women only (WOMEN) and among men only (MEN). All analyses were corrected for genomic control at the cohort-level. We excluded variants with minor allele frequency (MAF)<5% due to the low power to detect associations of such variants. We set a traditional genome-wide significance threshold at $P < 5 \times 10^{-8}$, the Bonferroni correction for the number of independent and common variants across the genome (~1 million SNPs). All p-values represent two-sided p-values unless otherwise specified. All regional association plots, Manhattan plots, and QQ plots were created using R version 3.1.1 (<https://cran.r-project.org/>). Linkage disequilibrium plots were created using SNAP³¹ and the gap R package (<https://www.jstatsoft.org/article/view/v023i08>).

To correct for multiple testing, false discovery rate (FDR) was calculated across the 27 ectopic fat GWAS scans using the qvalue R package (<http://github.com/jdstorey/qvalue>). FDR<1% was set as the multiple testing corrected significance threshold.

For mouse studies, individual cages of mice were randomly assigned in an un-blinded fashion to normal chow or high fat diet. Each *in vivo* study was conducted one time and no mice were excluded from the analyses. In the absence of *a priori* data regarding the variance of gene expression in the tissues of interest, we applied sample sizes that have in our experience been of sufficient size to detect a two-fold increase in gene expression. For normally distributed data from more than two groups (Shapiro-Wilk), an ANOVA test followed by Sidak's correction for multiple testing was conducted (Figures 1a,c,e). For non-normal data a Kruskal-Wallis test was used. For comparisons between two normally distributed groups (Figure 1b: chow versus high fat) a two-sided T-test was used, unless the data was non-normal, in which case a Mann-Whitney test was used. Data were expressed as mean, s.e.m. Significance was assigned for two-sided $p < 0.05$. Data were analyzed and graphed using JMP 10.0 (SAS institute) and Prism 6 (Graphpad).

Sensitivity Analyses

To ensure the newly identified loci from our multiethnic analysis were robust and not driven by statistical outliers related to ancestry, ancestry-specific meta-analysis results were compared with each other with respect to the minor allele, the minor allele frequency and direction of the Z-score association statistic (Supplementary Table 9). Due to the scaling differences in imaging modalities across each cohort and use of the sample size weighted meta-analysis heterogeneity statistics cannot be calculated.

The lead SNP for the *GSDMB* locus associated with SAT in women was not observed in non-European ancestry cohorts and thus was not included in this analysis. For each of the remaining 6 lead SNPs from the newly identified ectopic fat loci, Z scores were directionally consistent across ancestry-specific meta-analyses (please see Supplementary Figure 2 for forest plots of each locus and Supplementary Figure 3 for linkage disequilibrium [LD] plots across ancestry). For 5 of these loci, the minor allele was identical across ancestries; only the minor allele of rs2842895 (*RREB1*) differed between the European ancestry and African

ancestry cohorts. This observation may explain the slight attenuation in the association of *RREB1* and VATadjBMI after combining European and African ancestries in the multiethnic meta-analysis ($P_{\text{European-ancestry}}=5.8\times 10^{-9}$ to $P_{\text{multiethnic}}=1.1\times 10^{-8}$), although the multiethnic result remains genome-wide significant.

Analyses of Related Traits

For each SNP attaining genome-wide significance in association with any ectopic fat trait, we extracted association results in each strata of analysis (ALL, WOMEN, and MEN) for related ectopic fat traits within our study.

To investigate the association of the new ectopic fat loci with measures of generalized adiposity (BMI) and central obesity (WHR) - two traits that are strongly correlated with, but distinct from ectopic fat - we evaluated the lead genome-wide significant SNPs in publically available datasets from the most recent GIANT meta-analyses of BMI and WHR.^{14,15}

To investigate associations of new loci with cardio-metabolic traits that are epidemiologically associated with ectopic fat, cross-trait evaluations for the lead SNPs only were performed in the publically available datasets from the MAGIC (Meta-Analyses of Glucose and Insulin Consortium for fasting glucose and insulin³²), GLGC (Global Lipids Genetics Consortium for high-density lipoprotein cholesterol, triglycerides and total cholesterol³³), CARDIoGRAM+CAD consortium (Coronary ARtery Disease Genome wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics for coronary artery disease and myocardial infarction^{34,35}), ICBP (International Consortium for Blood Pressure for systolic and diastolic blood pressure³⁶), and DIAGRAM (DIAbetes Genetics Replication And Meta-analysis²⁵).

Analysis of general adiposity and central adiposity loci

To evaluate the relationship between the known 97 BMI and 49 WHR loci^{14,15} with ectopic fat traits, we examined the association for these loci with fat volume and relative fat volume traits among the combined multiethnic sample of women and men. Because the ectopic fat data may be underpowered to determine statistically significant results, we hypothesized that the direction of the BMI and WHR findings would be directionally consistent with the ectopic fat traits, even if the p-values were not significant. Binominal tests were used to test the significance of direction consistent associations (1-sided p-values). If the binominal test across the BMI or WHR loci was significant, a second 1-sided binominal test was performed evaluating consistency of associations restricting to SNPs with nominally significant associations ($P<0.05$).

Functional Profiling - Bioinformatics and Annotation

To further characterize novel genome-wide significant loci, the following bioinformatics databases were queried for the lead ectopic fat loci: GWAS Catalog (<https://www.ebi.ac.uk/gwas/>; access date: 10/15/2015) to investigate other traits associated with newly identified loci, and HaploReg²³ and RegulomeDB²⁴ to identify regulatory elements overlapping the loci for the index SNP and SNPs in LD with the index SNP ($r^2>0.8$; Supplementary Table 13). To contextualize the newly identified ectopic loci and the surrounding genes, SNIPPER

(<https://github.com/welchr/Snipper.git>) was used to search for biologically relevant mechanisms (Supplementary Table 14).

Variance Explained

The variance explained for each of the loci was approximated using the following formula $R^2 = \beta^2 \text{var}(\text{SNP}) / \text{var}(\text{ectopic fat trait})$, where β^2 is the estimated effect of the SNP on the ectopic fat trait, and $\text{var}(\text{SNP}) = 2 * \text{MAF}_{\text{SNP}} * (1 - \text{MAF}_{\text{SNP}})$. Because sample-size weighted fixed-effect meta-analysis does not estimate effect sizes, the beta-coefficient for the association between the SNP and ectopic fat trait and the variance of the ectopic fat trait were obtained from cohort level analysis per contributing study. The mean of the variance explained per locus across all contributing cohorts ranges from 0.1% to 4.4% (Supplementary Table 15).

Power Calculations

Power for discovery in the ectopic fat genomewide scan was calculated using GWAPower³⁷ using the range of sample size in this study (5,842–18,332 participants) and setting $\alpha = 5 \times 10^{-8}$. For the smallest sample size analyzed (N=5,842) we had 80% power to detect loci explaining at least 0.64% of the trait variance. For the largest sample size analyzed (N=18,332), we had 80% power to detect loci explaining at least 0.20% of the trait variance. For example, our novel loci explained from 0.15–4.4% of the trait variance for ectopic fat as seen in Supplementary Table 15.

To address the power to detect associations for the lookup analyses, we used GWAPower³⁷ with the maximum sample sizes from each of the quantitative trait datasets (52,000–94,000 participants), a modest range of variance explained (0.01–0.05%; based on the variance explained for each locus [0.1–4.4%] and the age-adjusted correlations between ectopic fat and the cardiometabolic trait of interest [$R^2 = 0.02$ –0.46]) and a Bonferroni corrected $\alpha = 7.4 \times 10^{-4}$ (~0.05/66 pairs of SNP-trait associations). For the smallest dataset (Fasting Insulin, N~52,000), we had 80% power to detect loci explaining at least 0.030% of the variance in fasting insulin. For the largest dataset (HDL-C and total cholesterol, N~94,000), we had 80% power to detect loci explaining 0.018% of the variance in HDL-C or total cholesterol. These calculations indicate that we largely had adequate power for a large portion of the SNP-trait associations.

eQTL analysis

Using a curated collection of 6 eQTL datasets in adipose-related tissues, index SNPs at newly identified ectopic fat loci were examined in association with transcript expression. Datasets were collected through publications, publically available sources, or private collaboration. The eQTL datasets met criteria for statistical thresholds for SNP-gene transcript associations as described in the original papers and were limited to index SNPs and SNPs in LD with the index SNP ($r^2 > 0.8$) across all ancestries available in the 1000 Genomes Project pilot (SNAP³¹). A general overview of the larger collection of more than 50 eQTL studies from which the adipose-related datasets (omental, visceral and subcutaneous adipose,^{38–42}) were derived from has been published.⁴³ Additional eQTL data was integrated from online sources including ScanDB, the Broad Institute GTEx Portal, and

the Pritchard Lab (eqtl.uchicago.edu). Results for GTEx Analysis V4 for subcutaneous adipose tissue were downloaded from the GTEx Portal and then additionally filtered as described below (www.gtexportal.org⁴¹). Splicing QTL (sQTL) results generated with sQTLseeker with false discovery rate $P = 0.05$ were retained. For all gene-level eQTLs, if at least 1 SNP passed the tissue-specific empirical threshold in GTEx, the best SNP for that eQTL was always retained. All gene-level eQTL SNPs with $P < 1.67 \times 10^{-11}$ were also retained, reflecting a global threshold correction of $P = 0.05 / (30,000 \text{ genes} \times 1,000,000 \text{ tests})$.

Cis-eQTL analysis showed SNPs at *ENSA* (a locus identified in association with PAT) was correlated with multiple transcripts (*MRPS21*, *CTSK* and *LASS2*, $P < 10^{-4}$) in subcutaneous and omental adipose tissue (Supplementary Table 16), suggesting these may be the relevant transcripts at this locus and not *ENSA*, the closest gene to the lead association signal. However, the *ENSA* locus was not selected for functional validation, as there were too many genes in the region to practically follow up. No other eQTLs were identified.

Characterization in Model Organisms

Selection of Loci for Characterization—For functional follow-up and characterization of ectopic fat loci, four gene-trait associations were selected based on visual examination of regional association plots (Supplementary Figures 1a–g) for a localized association within a gene body at each locus (*RREB1*, *ATXN1* and *UBE2E2*) or localized association near the gene body and the lack of other genes within 1Mbp of the lead SNP (*EBFI*) to increase the probability of experimentally testing the likely causal gene in murine models.

Mouse studies—Experiments were approved by and in compliance with the ethical regulations of the Harvard Medical Area Standing Committee on Animals. Male C57BL/6 mice were purchased from Charles River and housed at $22 \pm 2^\circ\text{C}$, with a 12h light (0700–1900 h), 12h dark (1900–0700 h) cycle and *ad libitum* access to food and water. With the exception of the data shown in Supplementary Figure 6, experiments were conducted in male mice. Diet-induced obesity was modeled with high fat (D12492) and control chow (D12450J) matched for sucrose content (Research Diets, Inc.). Adipose tissue was harvested, homogenized in Trizol (Life Technologies), and RNA extracted according to the manufacturers protocol. cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies). qPCR was performed using iTaq Universal SYBR Green Supermix (Bio-Rad, Hercules, CA) on an iCycler (Bio-Rad) instrument. See Supplementary Table 17 for primer sequences used in these analyses. Gene expression was normalized to 18S. The delta-delta CT method was utilized to calculate fold change in transcript levels.

Comparison of baseline adipose-specific expression of *Atxn1*—Given that the SNP-ectopic fat association for *ATXN1* was confined to men, we assessed gender-specific effects in mice of *Atxn1* expression. There was no detectable gender effect on the baseline, adipose-specific expression of *Atxn1* (Supplementary Figure 6).

Adipogenesis assay—Adipose tissue from C57BL/6 mice was minced and digested with collagenase D (Roche) in a shaking water bath (37C, 225rpm, 40min). The digest was

centrifuged at 400g for 10 min. Pelleted stromal vascular cells were filtered (40µm) and then washed with PBS and subjected to additional negative selection (CD31⁻/lineage⁻) adapted from previously performed methods⁴⁴ using antibody coated microbeads (Miltenyi Biotec). Cells were cultured to confluence in collagen-coated plates and stimulated with dexamethasone, insulin and 3-isobutyl-1-methylxanthine to induce adipogenic differentiation. For genetic loss of function assays, validated shRNA sequences (Broad, *Ube2e2*: TRCN0000040962; *Atxn1*: TRCN0000240655) or scramble sequence were subcloned into a retroviral vector (pMKO.1). Gene knock-down efficiency was confirmed by qPCR in 3T3L1 cells, in each instance reproducibly achieving a minimum of 60% reduction of transcriptional activity. Differentiation into mature lipid-containing adipocytes was determined by oil-red-o (ORO) staining and quantified by measuring alcohol-extracted ORO dye at optical density 520 nm (OD₅₂₀).

Cohort Specific Acknowledgements and Funding—Please see the Supplementary Note for acknowledgements and funding statements from all participating cohorts.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Audrey Y Chu^{1,2,48}, Xuan Deng^{3,48}, Virginia A Fisher^{3,48}, Alexander Drong⁴, Yang Zhang^{5,6}, Mary F Feitosa⁷, Ching-Ti Liu³, Olivia Weeks⁶, Audrey C Choh⁸, Qing Duan⁹, Thomas D Dyer¹⁰, John D Eicher¹, Xiuqing Guo¹¹, Nancy L Heard-Costa³, Tim Kacprowski^{12,13}, Jack W Kent Jr¹⁴, Leslie A Lange⁹, Xinggang Liu¹⁵, Kurt Lohman^{16,17}, Lingyi Lu¹⁷, Anubha Mahajan⁴, Jeffrey R O'Connell¹⁵, Ankita Parihar¹⁵, Juan M Peralta¹⁰, Albert V Smith^{18,19}, Yi Zhang²⁰, Georg Homuth¹², Ahmed H Kissebah^{20,49}, Joel Kullberg²¹, René Laqua²², Lenore J Launer²³, Matthias Nauck^{24,13}, Michael Olivier^{14,20}, Patricia A Peyser²⁵, James G Terry²⁶, Mary K Wojczynski⁷, Jie Yao¹¹, Lawrence F Bielak²⁵, John Blangero¹⁰, Ingrid B Borecki⁷, Donald W Bowden^{27,28}, John Jeffrey Carr²⁶, Stefan A Czerwinski²⁹, Jingzhong Ding^{16,30}, Nele Friedrich^{24,13}, Vilmunder Gudnason^{18,19}, Tamara B Harris²³, Erik Ingelsson^{31,32}, Andrew D Johnson¹, Sharon LR Kardia²⁵, Carl D Langefeld¹⁷, Lars Lind²¹, Yongmei Liu^{16,33}, Braxton D Mitchell^{15,34}, Andrew P Morris^{35,4}, Thomas H Mosley Jr³⁶, Jerome I Rotter¹¹, Alan R Shuldiner¹⁵, Bradford Towne⁸, Henry Völzke^{37,13,38}, Henri Wallaschofski²⁴, James G Wilson³⁹, Matthew Allison⁴⁰, Cecilia M Lindgren⁴¹, Wolfram Goessling^{6,42,43,44,45}, L Adrienne Cupples^{1,3,50}, Matthew L Steinhauser^{5,6,45,46,50}, and Caroline S Fox^{1,47,50}

Affiliations

¹NHLBI's Framingham Heart Study, Framingham MA USA ²Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston MA USA ³Department of Biostatistics, Boston University School of Public Health, Boston MA USA ⁴Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford UK ⁵Department of Medicine, Brigham and Women's Hospital and Harvard

Medical School, Boston MA USA ⁶Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston MA USA ⁷Department of Genetics, Washington University, St. Louis MO USA ⁸Division of Epidemiology and Biostatistics, Department of Population and Public Health Sciences, Wright State University Boonshoft School of Medicine, Dayton OH USA ⁹Department of Genetics, University of North Carolina, Chapel Hill NC USA ¹⁰South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio & University of Texas of the Rio Grande Valley, Brownsville TX USA ¹¹Institute for Translational Genomics and Population Sciences, Department of Pediatrics, LABioMed at Harbor-UCLA Medical Center, Torrance CA USA ¹²Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald Germany ¹³German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Germany ¹⁴TOPS Nutrition and Obesity Research Center, Department of Genetics, Texas Biomedical Research Institute, San Antonio TX USA ¹⁵University of Maryland School of Medicine, Baltimore MD USA ¹⁶Wake Forest School of Medicine, Winston-Salem NC USA ¹⁷Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem NC USA ¹⁸Icelandic Heart Association, Kopavogur Iceland ¹⁹Faculty of Medicine, University of Iceland, Reykjavik Iceland ²⁰TOPS Obesity and Metabolic Research Center, Biotechnology and Bioengineering Center, Department of Physiology at the Medical College of Wisconsin, WI USA ²¹Department of Surgical Sciences, Section of Radiology, Uppsala University, Uppsala Sweden ²²Department of Neuroradiology, University Hospital Berne, Berne Switzerland ²³National Institute on Aging, Intramural Research Program, National Institutes of Health, Bethesda MD USA ²⁴Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald Germany ²⁵Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor MI USA ²⁶Departments of Radiology and Radiologic Sciences, Cardiovascular Medicine and Biomedical Informatics, Vanderbilt University Medical Center, Nashville TN USA ²⁷Center for Genomics and Personalized Medicine Research, Wake Forest University Health Sciences, Winston-Salem NC USA ²⁸Department of Biochemistry, Center for Diabetes Research, and Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem NC USA ²⁹Department of Epidemiology, Human Genetics and Environmental Sciences, University of Texas Health Science Center (UTHealth) School of Public Health Brownsville Campus, Brownsville TX USA ³⁰Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem NC USA ³¹Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala Sweden ³²Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford CA USA ³³Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem NC USA ³⁴Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore MD USA ³⁵Department of Biostatistics, University of Liverpool, Liverpool UK ³⁶University of Mississippi Medical Center, Jackson MS USA ³⁷Institute for Community Medicine, University Medicine

Greifswald, Greifswald Germany ³⁸German Centre for Diabetes Research (DZD), Site Greifswald, Germany ³⁹Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson MS USA ⁴⁰Division of Preventive Medicine, Department of Family Medicine and Public Health, UC San Diego School of Medicine, San Diego CA USA ⁴¹Li Ka Shing Centre for Health Information and Discovery, The Big Data Institute, University of Oxford, Oxford, UK ⁴²Harvard Stem Cell Institute, Cambridge MA USA ⁴³Gastroenterology Division, Brigham and Women's Hospital, Harvard Medical School, Boston MA USA ⁴⁴Dana-Farber Cancer Institute, Boston MA USA ⁴⁵Broad Institute of MIT and Harvard, Cambridge MA USA ⁴⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston MA USA ⁴⁷Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston MA USA

Acknowledgments

Please see Supplementary Note for Acknowledgments and Funding Sources.

References

1. Ding J, et al. The association of regional fat depots with hypertension in older persons of white and African American ethnicity. *Am J Hypertens.* 2004; 17:971–976. DOI: 10.1016/j.amjhyper.2004.05.001 [PubMed: 15485762]
2. Goodpaster BH, et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. *Diabetes Care.* 2003; 26:372–379. [PubMed: 12547865]
3. Hayashi T, et al. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. *Ann Intern Med.* 2004; 140:992–1000. [PubMed: 15197016]
4. Kanaya AM, et al. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. *Diabetes Care.* 2004; 27:1375–1380. [PubMed: 15161791]
5. Nicklas BJ, et al. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. *Diabetes Care.* 2003; 26:141–420.
6. Kaess BM, et al. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. *Diabetologia.* 2012; 55:2622–2630. DOI: 10.1007/s00125-012-2639-5 [PubMed: 22898763]
7. Rosenquist KJ, et al. Visceral and subcutaneous fat quality and cardiometabolic risk. *JACC Cardiovasc Imaging.* 2013; 6:762–771. DOI: 10.1016/j.jcmg.2012.11.021 [PubMed: 23664720]
8. Britton KA, et al. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. *J Am Coll Cardiol.* 2013; 62:921–925. DOI: 10.1016/j.jacc.2013.06.027 [PubMed: 23850922]
9. Alvey NJ, et al. Association of fat density with subclinical atherosclerosis. *J Am Heart Assoc.* 2014; 3
10. Rosenquist KJ, et al. Fat quality and incident cardiovascular disease, all-cause mortality, and cancer mortality. *J Clin Endocrinol Metab.* 2015; 100:227–234. DOI: 10.1210/jc.2013-4296 [PubMed: 25226289]
11. Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association Between Visceral and Subcutaneous Adipose Depots and Incident Cardiovascular Disease Risk Factors. *Circulation.* 2015; 132:1639–1647. DOI: 10.1161/CIRCULATIONAHA.114.015000 [PubMed: 26294660]
12. Fox CS, et al. Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women. *PLoS genetics.* 2012; 8:e1002695. [PubMed: 22589738]

13. Fox CS, et al. Genome-wide association of pericardial fat identifies a unique locus for ectopic fat. *PLoS genetics*. 2012; 8:e1002705. [PubMed: 22589742]
14. Shungin D, et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature*. 2015; 518:187–196. DOI: 10.1038/nature14132 [PubMed: 25673412]
15. Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015; 518:197–206. DOI: 10.1038/nature14177 [PubMed: 25673413]
16. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet*. 1998; 62:1198–1211. DOI: 10.1086/301844 [PubMed: 9545414]
17. Fox CS, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation*. 2007; 116:39–48. DOI: 10.1161/CIRCULATIONAHA.106.675355 [PubMed: 17576866]
18. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010; 26:2190–2191. DOI: 10.1093/bioinformatics/btq340 [PubMed: 20616382]
19. Stouffer, SA., Suchman, EA., DeVinney, LC., Star, SA., Williams, RMJ. *Adjustment During Army Life*. Princeton University Press; 1949.
20. Baba S, Jacene HA, Engles JM, Honda H, Wahl RL. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. *J Nucl Med*. 2010; 51:24–50. DOI: 10.2967/jnumed.109.068775
21. Hu HH, Chung SA, Nayak KS, Jackson HA, Gilsanz V. Differential computed tomographic attenuation of metabolically active and inactive adipose tissues: preliminary findings. *J Comput Assist Tomogr*. 2011; 35:65–71. DOI: 10.1097/RCT.0b013e3181fc2150 [PubMed: 21245691]
22. Heid IM, et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. *Nat Genet*. 2010; 42:949–960. DOI: 10.1038/ng.685 [PubMed: 20935629]
23. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*. 2012; 40:D930–934. DOI: 10.1093/nar/gkr917 [PubMed: 22064851]
24. Boyle AP, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res*. 2012; 22:1790–1797. DOI: 10.1101/gr.137323.112 [PubMed: 22955989]
25. Replication DIG, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat Genet*. 2014; 46:234–244. DOI: 10.1038/ng.2897 [PubMed: 24509480]
26. Yamauchi T, et al. A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. *Nat Genet*. 2010; 42:864–868. DOI: 10.1038/ng.660 [PubMed: 20818381]
27. Hara K, et al. Genome-wide association study identifies three novel loci for type 2 diabetes. *Hum Mol Genet*. 2014; 23:239–246. DOI: 10.1093/hmg/ddt399 [PubMed: 23945395]
28. Zillikens MC, et al. Sex-specific genetic effects influence variation in body composition. *Diabetologia*. 2008; 51:2233–2241. DOI: 10.1007/s00125-008-1163-0 [PubMed: 18839131]
29. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol*. 2010; 34:816–834. DOI: 10.1002/gepi.20533 [PubMed: 21058334]
30. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS genetics*. 2009; 5:e1000529. [PubMed: 19543373]
31. Johnson AD, et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics*. 2008; 24:2938–2939. DOI: 10.1093/bioinformatics/btn564 [PubMed: 18974171]
32. Manning AK, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat Genet*. 2012; 44:659–669. DOI: 10.1038/ng.2274 [PubMed: 22581228]
33. Global Lipids Genetics C, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013; 45:127–283. DOI: 10.1038/ng.2797

34. Coronary Artery Disease Genetics, C. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. *Nat Genet.* 2011; 43:33–44. DOI: 10.1038/ng.782
35. Schunkert H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* 2011; 43:33–38. DOI: 10.1038/ng.784
36. International Consortium for Blood Pressure Genome-Wide Association, S. et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature.* 2011; 478:103–109. DOI: 10.1038/nature10405 [PubMed: 21909115]
37. Feng S, Wang S, Chen CC, Lan L. GWAPower: a statistical power calculation software for genome-wide association studies with quantitative traits. *BMC Genet.* 2011; 12:12. [PubMed: 21255436]
38. Emilsson V, et al. Genetics of gene expression and its effect on disease. *Nature.* 2008; 452:423–428. DOI: 10.1038/nature06758 [PubMed: 18344981]
39. Greenawalt DM, et al. A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. *Genome Res.* 2011; 21:1008–1016. DOI: 10.1101/gr.112821.110 [PubMed: 21602305]
40. Grundberg E, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. *Nat Genet.* 2012; 44:1084–1089. DOI: 10.1038/ng.2394 [PubMed: 22941192]
41. Consortium GT. The Genotype-Tissue Expression (GTEx) project. *Nat Genet.* 2013; 45:580–585. DOI: 10.1038/ng.2653 [PubMed: 23715323]
42. Foroughi Asl H, et al. Expression quantitative trait Loci acting across multiple tissues are enriched in inherited risk for coronary artery disease. *Circ Cardiovasc Genet.* 2015; 8:305–315. DOI: 10.1161/CIRCGENETICS.114.000640 [PubMed: 25578447]
43. Zhang X, et al. Synthesis of 53 tissue and cell line expression QTL datasets reveals master eQTLs. *BMC Genomics.* 2014; 15:532. [PubMed: 24973796]
44. Kim SM, et al. Loss of white adipose hyperplastic potential is associated with enhanced susceptibility to insulin resistance. *Cell metabolism.* 2014; 20:1049–1058. DOI: 10.1016/j.cmet.2014.10.010 [PubMed: 25456741]




Figure 1. Functional characterization of *Atxn1*, *Ebf1*, *Rreb1* and *Ube2e2*

(a,b,e) Data is displayed as box/whisker plots where the center line represents the median, box limits contain the 25th–75th percentiles, and whiskers span max/min values.

(a) Gene expression measured by qPCR in murine subcutaneous (SAT), perigonadal visceral (VAT), and pericardial (PAT) adipose tissues (n=6 mice). Statistical significance was assessed using ANOVA and Sidak’s correction for multiple comparisons.

(b) Gene expression measured by qPCR in murine adipose tissues after 8 weeks of high fat feeding compared to normal chow fed controls (n=5 mice per group). Statistical significance was assigned using a two-sided T-test.

(c) Gene expression measured by qPCR in cultured adipocyte progenitors isolated from the subcutaneous (SAT) or perigonadal visceral (VAT) depots (n=4 replicates). Cells were expanded to confluence and then collected at intervals after induction of adipogenic differentiation. Data displayed as mean, error bar=s.e.m. Statistical significance was assessed using ANOVA and Sidak’s correction for multiple comparisons to time 0.

(d) Oil-red-o staining of progenitors isolated from subcutaneous adipose and exposed to retroviral delivery of shRNA constructs during *ex vivo* expansion and induction of adipogenesis. Relative to control vector carrying a scramble sequence, shRNA constructs specific for *Atxn1* and *Ube2e2* impaired adipogenic differentiation. Scale=1mm.

(e) Oil-red-o stain was alcohol extracted and quantified at OD₅₂₀ (n=9 technical replicates). Statistical significance was assessed using ANOVA and Sidak’s correction for multiple comparisons to control (Scramble). Data representative of 3 independent experiments.

Table 1

SNPs associated with ectopic fat traits ($p < 5 \times 10^{-8}$)¹. Association statistics were obtained using a sample-size weighted fixed-effects meta-analysis implemented in METAL.^{18,19}

Locus ²	Trait	Strata	Lead SNP	Chr	SNPID	Position	A1 ³	A2 ⁴	Freq A1 ⁵	N	Z score	P-value ⁶
Fat Volume Traits^{7,8}												
NEW												
<i>ENSA</i>	PATadjHWt	ALL	rs6587515	1	rs6587515	148875512	a	g	0.09	11027	-5.94	2.8×10 ⁻⁹
<i>GRAMD3</i>	VATadjBMI	WOMEN	rs10060123	5	rs10060123	125711809	a	c	0.23	9623	5.47	4.5×10 ⁻⁸
<i>EBF1</i>	PATadjHWt	ALL	rs1650505	5	rs1650505	157962312	a	g	0.24	11566	-6.10	1.0×10 ⁻⁹
	PAT	ALL	rs2434264	5	rs2434264	157954781	t	g	0.61	11614	5.93	3.0×10 ⁻⁹
<i>RREB1</i>	VATadjBMI	ALL	rs2842895	6	rs2842895	7051315	c	g	0.50	17297	5.72	1.1×10 ⁻⁸
<i>GSDMB</i>	SAT	WOMEN	rs2123685	17	rs2123685	35307415	t	c	0.94	7137	5.52	3.4×10 ⁻⁸
KNOWN												
<i>TRIB2</i>	PATadjHWt	ALL							0.42	11572	-8.88	6.7×10 ⁻¹⁹
	PATadjHWt	MEN							0.43	5466	-6.68	2.4×10 ⁻¹¹
	PATadjHWt	WOMEN	rs10198628	2	rs10198628	12881948	a	g	0.42	6106	-6.02	1.8×10 ⁻⁹
	PAT	ALL							0.42	11605	-7.87	3.7×10 ⁻¹⁵
<i>FTO</i>	SAT	ALL	rs7185735	16	rs7185735	52380152	a	g	0.58	17812	-6.05	1.4×10 ⁻⁹
Fat Attenuation Traits^{7,8}												
NEW												
<i>ATXN1</i>	SATHU	MEN	rs2237199	6	rs2237199	16538000	a	g	0.11	5780	5.67	1.4×10 ⁻⁸
Relative Fat Distribution Traits^{7,8}												
NEW												
<i>UBE2E2</i>	VAT/SAT ratio	ALL	rs7374732	3	rs7374732	23178458	t	c	0.69	18205	-6.29	3.1×10 ⁻¹⁰
	VAT/SAT ratio adjBMI	ALL							0.69	18190	-5.64	1.7×10 ⁻⁸
KNOWN												
<i>LYP1L1</i>	VAT/SAT ratio	ALL	rs6689335	1	rs6689335	217695305	t	c	0.59	15214	-5.59	2.3×10 ⁻⁸
	VAT/SAT ratio adjBMI	ALL							0.59	15199	-5.53	3.2×10 ⁻⁸

Locus ²	Trait	Strata	Lead SNP	Chr	SNPID	Position	A1 ³	A2 ⁴	Freq A1 ⁵	N	Z score	P-value ⁶
LY86	VAT/SAT ratio	ALL	rs912056	6	rs912056	6681196	a	t	0.35	17387	-5.96	2.5×10 ⁻⁹
	VAT/SAT ratio adjBMI	ALL										2.3×10 ⁻⁹

¹ SNPs are grouped by ectopic fat trait and are listed by new discoveries and then previously identified loci. Any association attaining genome-wide significance ($p < 5 \times 10^{-8}$) is listed.

² Conventional locus name based on closest gene in the region

³ A1 is the coded allele

⁴ A2 is the non-coded allele

⁵ FreqA1 is the allele frequency of Allele 1

⁶ P-values are double genomic control corrected

⁷ European and African ancestry cohorts contributed to all ectopic fat traits; Chinese and Hispanic ancestry cohorts contributed only to pericardial volume traits

⁸ Abbreviations:

- SAT - Subcutaneous Adipose Tissue Volume
- VAT - Visceral Adipose Tissue Volume
- PAT - Pericardial Adipose Tissue Volume
- SATHU - Subcutaneous Adipose Tissue Attenuation
- VATHU - Visceral Adipose Tissue Attenuation
- VAT/SAT ratio - Visceral to Subcutaneous Adipose Tissue Volume Ratio
- adjBMI - Model Adjusted for BMI
- adjHtWt - Model Adjusted for Height and Weight